Abstract
Mammalian tissues express at least two cannabinoid receptor types, CB1 and CB2, both G protein coupled. CB1 receptors are found predominantly at nerve terminals where they mediate inhibition of transmitter release. CB2 receptors occur mainly on immune cells, one of their roles being to modulate cytokine release. Endogenous agonists for cannabinoid receptors also exist, and are all eicosanoids. The first-discovered of these ‘endocannabinoids’ was arachidonoylethanolamide and there is convincing evidence that this ligand and some of its metabolites can activate vanilloid VRI (TRPV1) receptors. Certain cannabinoids also appear to have TRPV1-like and/or non-CB1, non-CB2, non-TRPV1 targets. Several CB1- and CB2-selective agonists and antagonists have been developed. Antagonists include the CB1-selective SR141716A, AM251, AM281 and LY320135, and the CB2-selective SR144528 and AM630. These all behave as inverse agonists, one indication that CB1 and CB2 receptors can exist in a constitutively active state. ‘Neutral’ cannabinoid receptor antagonists have also been developed. CB1 and/or CB2 receptor activation appears to ameliorate inflammatory and neuropathic pain and certain multiple sclerosis symptoms. This might be exploited clinically by using CB1, CB2 or CB1/CB2 agonists, or inhibitors of the membrane transport or catabolism of endocannabinoids that are released in increased amounts, at least in animal models of pain and multiple sclerosis. We have recently discovered the presence of an allosteric site on the CB1 receptor. Consequently, it may also prove possible to enhance ‘autoprotective’ effects of released endocannabinoids with CB1 allosteric enhancers or, indeed, to reduce proposed ‘autoimpairing’ effects of released endocannabinoids such as excessive food intake with CB1 allosteric antagonists.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA et al. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 2002; 54: 161–202.
Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TT . Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990; 346: 561–564.
Munro S, Thomas KL, Abu-Shaar M . Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993; 365: 61–65.
Mu J, Zhuang S-Y, Kirby MT, Hampson RE, Deadwyler SA . Cannabinoid receptors differentially modulate potassium A and D currents in hippocampal neurons in culture. J Pharmacol Exp Ther 1999; 291: 893–902.
Pertwee RG . Pharmacological actions of cannabinoids. In: Pertwee RG (ed) Cannabinoids. Handbook of Experimental Pharmacology. Springer-Verlag: Heidelberg, 2005, pp 1–51.
Pertwee RG, Thomas A, Stevenson LA, Maor Y, Mechoulam R . Evidence that (–)-7-hydroxy-4′-dimethylheptyl-cannabidiol activates a non-CB1, non-CB2, non-TRPV1 target in the mouse vas deferens. Neuropharmacology 2005; 48: 1139–1146.
Berry EM, Mechoulam R . Tetrahydrocannabinol and endocannabinoids in feeding and appetite. Pharmacol Ther 2002; 95: 185–190.
Pertwee RG . Cannabinoid receptors and pain. Prog Neurobiol 2001; 63: 569–611.
Pertwee RG . Novel pharmacological targets for cannabinoids. Curr Neuropharmacol 2004; 2: 9–29.
De Petrocellis L, Cascio MG, Di Marzo V . The endocannabinoid system: a general view and latest additions. Br J Pharmacol 2004; 141: 765–774.
Pertwee RG, Ross RA . Cannabinoid receptors and their ligands. Prostaglandins Leukot Essent Fatty Acids 2002; 66: 101–121.
Pertwee RG . Cannabinoids and multiple sclerosis. Pharmacol Ther 2002; 95: 165–174.
Porter AC, Sauer J-M, Knierman MD, Becker GW, Berna MJ, Bao J et al. Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor. J Pharmacol Exp Ther 2002; 301: 1020–1024.
Pertwee RG . Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther 1997; 74: 129–180.
Sim-Selley LJ . Regulation of cannabinoid CB1 receptors in the central nervous system by chronic cannabinoids. Crit Rev Neurobiol 2003; 15: 91–119.
Massi P, Patrini G, Rubino T, Fuzio D, Parolaro D . Changes in rat spleen cannabinoid receptors after chronic CP-55,940: an autoradiographic study. Pharmacol Biochem Behav 1997; 58: 73–78.
Bouaboula M, Dussossoy D, Casellas P . Regulation of peripheral cannabinoid receptor CB2 phosphorylation by the inverse agonist SR 144528: implications for receptor biological responses. J Biol Chem 1999; 274: 20397–20405.
Pertwee RG . Inverse agonism and neutral antagonism at cannabinoid CB1 receptors. Life Sci 2005; 76: 1307–1324.
Pan X, Ikeda SR, Lewis DL . SR 141716A acts as an inverse agonist to increase neuronal voltage-dependent Ca2+ currents by reversal of tonic CB1 cannabinoid receptor activity. Mol Pharmacol 1998; 54: 1064–1072.
Savinainen JR, Saario SM, Niemi R, Järvinen T, Laitinen JT . An optimized approach to study endocannabinoid signaling: evidence against constitutive activity of rat brain adenosine A1 and cannabinoid CB1 receptors. Br J Pharmacol 2003; 140: 1451–1459.
Breivogel CS, Griffin G, Di Marzo V, Martin BR . Evidence for a new G protein-coupled cannabinoid receptor in mouse brain. Mol Pharmacol 2001; 60: 155–163.
Guzmán M . Cannabinoids: potential anticancer agents. Nat Rev Cancer 2003; 3: 745–755.
Tomida I, Pertwee RG, Azuara-Blanco A . Cannabinoids and glaucoma. Br J Ophthalmol 2004; 88: 708–713.
Malan TP, Ibrahim MM, Vanderah TW, Makriyannis A, Porreca F . Inhibition of pain responses by activation of CB2 cannabinoid receptors. Chem Phys Lipids 2002; 121: 191–200.
Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rössner S . Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005; 365: 1389–1397.
Després J-P, Golay A, Sjöström L . Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005; 353: 2121–2134.
Price TJ, Patwardhan A, Akopian AN, Hargreaves KM, Flores CM . Modulation of trigeminal sensory neuron activity by the dual cannabinoid-vanilloid agonists anandamide, N-arachidonoyl-dopamine and arachidonyl-2-chloroethylamide. Br J Pharmacol 2004; 141: 1118–1130.
Baker CL, McDougall JJ . The cannabinomimetic arachidonyl-2-chloroethylamide (ACEA) acts on capsaicin-sensitive TRPV1 receptors but not cannabinoid receptors in rat joints. Br J Pharmacol 2004; 142: 1361–1367.
Price MR, Baillie GL, Thomas A, Stevenson LA, Easson M, Goodwin R et al. Allosteric modulation of the cannabinoid CB1 receptor. Mol Pharmacol 2005; 68: 1484–1495.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Pertwee, R. The pharmacology of cannabinoid receptors and their ligands: an overview. Int J Obes 30 (Suppl 1), S13–S18 (2006). https://doi.org/10.1038/sj.ijo.0803272
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.ijo.0803272
Keywords
This article is cited by
-
Potent dual MAGL/FAAH inhibitor AKU-005 engages endocannabinoids to diminish meningeal nociception implicated in migraine pain
The Journal of Headache and Pain (2023)
-
Possible actions of cannabidiol in obsessive-compulsive disorder by targeting the WNT/β-catenin pathway
Molecular Psychiatry (2022)
-
Cannabinoid receptor type 1 antagonists alter aspects of risk/reward decision making independent of toluene-mediated effects
Psychopharmacology (2022)
-
Cannabinoid Type 1 Receptors in the Basolateral Amygdala Regulate ACPA-Induced Place Preference and Anxiolytic-Like Behaviors
Neurochemical Research (2022)
-
Modulation of Excitatory Synaptic Transmission During Cannabinoid Receptor Activation
Cellular and Molecular Neurobiology (2022)